MNKD

MannKind Corporation (MNKD) | Rumor.io

MannKind

MNKD

Attention (50-day avg)0.01%

Attention rank (50-day avg)#539

Bullish sentiment (50-day avg)75%

Price to earnings ratio193.5

Market capitalization1.1B

Earnings per share-0.15

Dividend yield (TTM)—

Revenue (annual)349M

Net income (annual)5.9M

Social

What share of all stock conversation is about MNKD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.01	0.01% +0	0.01% 0	0.01% -0.02

Sep 29

Investors should consider MannKind's strategic positioning in the biopharmaceutical landscape, with a commitment to innovative therapies for chronic conditions and strong revenue growth.
The company's stock is trading below its 50-day and 200-day moving averages, suggesting a potential buying opportunity for investors speculating on a rebound.
Afrezza, MannKind's inhaled insulin product, has seen recent script growth, with 428 new refills and 487 total refills for the week ending 9/18/26.

Generated by AI

Sentiment

Of the messages about MNKD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	82.61% +22.61	68.18% +4.69	70.06% -12.58	78.56% -3.28
Bearish	17.39% -22.61	31.82% -4.69	29.94% +12.58	21.44% +3.28

Bullish· Sep 25

The company's CEO, Mike C., has made significant improvements and has a clear strategy for growth, which is being positively received by Wall Street.
The rapid growth of Readyflow, a product launched by MannKind Corporation, is a key indicator of the company's success, with some analysts suggesting that sales may already be exceeding 2 million per week.
Despite some criticism, the company's CEO has done a remarkable job in turning MannKind Corporation around from the verge of bankruptcy and delisting, and many believe that the best is yet to come.

Bearish· Sep 24

The CEO's actions are seen as a major reason for the company's decline, with some accusing him of stealing from shareholders and living a luxurious lifestyle on their expense.
The company's track record under the CEO's leadership since 2017 has been disastrous, with multiple failed projects and a net loss of $19.0 million.
The CEO's strategy of buying up small biotech companies to create the illusion of progress has been criticized, and many believe the company is on a path to bankruptcy.

Generated by AI

Topics

Of the messages about MNKD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	44.44%	42.31%	63.56%	42.53%
Technical Analysis	55.56%	38.46%	26.27%	36.96%
Analysts	0%	15.38%	7.63%	11.37%
Earnings	0%	0%	1.27%	5.37%
Controversies	0%	3.85%	1.27%	3.29%
Macro	0%	0%	0%	0.48%

Earnings· Nov 1

$MNKD reported Q3 EPS of $(0.16), up from $(0.31) YoY, with sales of $4.469M, up from $2.043M YoY.
The company beat consensus earnings per share, reporting a loss of $0.16, which was better than the expected loss of $0.18.
$MNKD's Q3 earnings were considered solid, but the stock may still be subject to bear raids due to market expectations.

Analysts· Jan 7

Goldman Sachs upgraded MannKind Corporation (MNKD) from SELL to BUY.
Griffin Securities also upgraded MNKD to BUY with a price target of $4.
JPMorgan Chase & Co. reiterated an Underweight rating for MannKind Corporation (MNKD).

Announcements· Jul 24

MannKind Corporation ($MNKD) announces FDA approval of Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease, with a 70% reduction in manufacturing cost.
The company expects the autoinjector to be available before the end of August and will focus on getting 60 primary IDNs to adopt it, aiming to significantly reduce their costs.
MannKind also announces a $50 million private placement, led by Frazier Life Sciences, with shares issued at $3.89 and pre-funded warrants at $3.88, to be used for general corporate purposes, including a $45 million contingent value rights payment.

Controversies· Jan 6

Some investors believe MannKind Corporation should file a lawsuit against Sanofi, citing similarities with a previous case where Sanofi was sued for similar actions.
Rosen Law Firm has announced an investigation into securities claims against MannKind Corporation, which may lead to a lawsuit.
Shareholders are advised to contact Khang & Khang LLP for more information about the investigation and potential lawsuit against MannKind Corporation.

Technical Analysis· Sep 2

$MNKD has a strong bullish chart with a recent 30% upswing and a 50% increase in 2 weeks.
The stock has reached its 52-week high and is expected to continue rallying in September, with a potential breakout above $6.50.
$MNKD is overbought and may drop to $5.04 or $5.7-5.8 in the near future, unless positive news is released, making it a potential short or buy opportunity.

Generated by AI

Community

Of the messages about MNKD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.24%	89.86%	91.29%	88.65%
Newcomers	11.76%	10.14%	8.71%	11.35%

Regulars· Sep 29

The company's strategic positioning in the biopharmaceutical landscape is attracting attention, with its commitment to innovative therapies for chronic conditions and strong revenue growth making it a noteworthy candidate for investors in healthcare innovation.
The recent pediatric sales data for Afrezza, with 428 new scripts and 487 refills, is being closely watched, and the company's ability to show strong patient demand by the time of its 3Q 2026 earnings report in November will be crucial.
Institutional ownership is currently at 70-80%, and despite some speculation about market manipulation, the stock's trading below its 50-day and 200-day moving averages and its neutral Relative Strength Index (RSI) position suggest a potential buying opportunity for investors.

Newcomers· Sep 22

Some users are speculating that MannKind Corporation may revisit the $2 price range again.
There is a theory that a wealthy individual, possibly a "rich lady boy," is buying up shares of MannKind Corporation.
Newcomers are taking note of MannKind Corporation's recent impressive recovery and are suggesting that it's a good time to follow the stock, with some users even loading up on dips.

Generated by AI

MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase

12d agoYahoo Finance

MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses

On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. The deal hands MannKind an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, without saddling it with the […]

14d agoca.finance.yahoo.com

Also Discussed

Investors talking about MNKD also mention

#	Name	Attention
1	Sanofi ADRSNY	0%-0.01
2	United Therapeutics CorporationUTHR	0%-0.01
3	XOMA CorporationXOMA	0%0
4	BDSI - BioDelivery Sciences International, Inc.	——
5	NAVB - Navidea Biopharmaceuticals, Inc.	——
6	Liquidia CorporationLQDA	0.01%0
7	El Pollo Loco Holdings, Inc.LOCO	0%0
8	Halozyme Therapeutics Inc.HALO	0%0
9	iShares Biotechnology ETFIBB	0.01%0
10	Ballard Power Systems Inc.BLDP	0%0

MannKind Corporation

Healthcare
Biotechnology

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion. The company also markets Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension, extending its presence in specialty respiratory care. MannKind Corporation serves patients and healthcare providers across endocrine and lung disease markets, with products designed to address chronic conditions that require convenient, patient-centered treatment options. Headquartered in Danbury, Connecticut, MannKind Corporation operates as a focused healthcare business centered on innovative drug delivery and disease management solutions.

Website

Location

1 Casper Street

Danbury, CT, 06810

United States

Social

What share of all stock conversation is about MNKD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.01	0.01% +0	0.01% 0	0.01% -0.02

Sep 29

Investors should consider MannKind's strategic positioning in the biopharmaceutical landscape, with a commitment to innovative therapies for chronic conditions and strong revenue growth.
The company's stock is trading below its 50-day and 200-day moving averages, suggesting a potential buying opportunity for investors speculating on a rebound.
Afrezza, MannKind's inhaled insulin product, has seen recent script growth, with 428 new refills and 487 total refills for the week ending 9/18/26.

Generated by AI

Sentiment

Of the messages about MNKD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	82.61% +22.61	68.18% +4.69	70.06% -12.58	78.56% -3.28
Bearish	17.39% -22.61	31.82% -4.69	29.94% +12.58	21.44% +3.28

Bullish· Sep 25

The company's CEO, Mike C., has made significant improvements and has a clear strategy for growth, which is being positively received by Wall Street.
The rapid growth of Readyflow, a product launched by MannKind Corporation, is a key indicator of the company's success, with some analysts suggesting that sales may already be exceeding 2 million per week.
Despite some criticism, the company's CEO has done a remarkable job in turning MannKind Corporation around from the verge of bankruptcy and delisting, and many believe that the best is yet to come.

Bearish· Sep 24

The CEO's actions are seen as a major reason for the company's decline, with some accusing him of stealing from shareholders and living a luxurious lifestyle on their expense.
The company's track record under the CEO's leadership since 2017 has been disastrous, with multiple failed projects and a net loss of $19.0 million.
The CEO's strategy of buying up small biotech companies to create the illusion of progress has been criticized, and many believe the company is on a path to bankruptcy.

Generated by AI

Topics

Of the messages about MNKD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	44.44%	42.31%	63.56%	42.53%
Technical Analysis	55.56%	38.46%	26.27%	36.96%
Analysts	0%	15.38%	7.63%	11.37%
Earnings	0%	0%	1.27%	5.37%
Controversies	0%	3.85%	1.27%	3.29%
Macro	0%	0%	0%	0.48%

Earnings· Nov 1

$MNKD reported Q3 EPS of $(0.16), up from $(0.31) YoY, with sales of $4.469M, up from $2.043M YoY.
The company beat consensus earnings per share, reporting a loss of $0.16, which was better than the expected loss of $0.18.
$MNKD's Q3 earnings were considered solid, but the stock may still be subject to bear raids due to market expectations.

Analysts· Jan 7

Goldman Sachs upgraded MannKind Corporation (MNKD) from SELL to BUY.
Griffin Securities also upgraded MNKD to BUY with a price target of $4.
JPMorgan Chase & Co. reiterated an Underweight rating for MannKind Corporation (MNKD).

Announcements· Jul 24

MannKind Corporation ($MNKD) announces FDA approval of Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease, with a 70% reduction in manufacturing cost.
The company expects the autoinjector to be available before the end of August and will focus on getting 60 primary IDNs to adopt it, aiming to significantly reduce their costs.
MannKind also announces a $50 million private placement, led by Frazier Life Sciences, with shares issued at $3.89 and pre-funded warrants at $3.88, to be used for general corporate purposes, including a $45 million contingent value rights payment.

Controversies· Jan 6

Some investors believe MannKind Corporation should file a lawsuit against Sanofi, citing similarities with a previous case where Sanofi was sued for similar actions.
Rosen Law Firm has announced an investigation into securities claims against MannKind Corporation, which may lead to a lawsuit.
Shareholders are advised to contact Khang & Khang LLP for more information about the investigation and potential lawsuit against MannKind Corporation.

Technical Analysis· Sep 2

$MNKD has a strong bullish chart with a recent 30% upswing and a 50% increase in 2 weeks.
The stock has reached its 52-week high and is expected to continue rallying in September, with a potential breakout above $6.50.
$MNKD is overbought and may drop to $5.04 or $5.7-5.8 in the near future, unless positive news is released, making it a potential short or buy opportunity.

Generated by AI

Community

Of the messages about MNKD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.24%	89.86%	91.29%	88.65%
Newcomers	11.76%	10.14%	8.71%	11.35%

Regulars· Sep 29

The company's strategic positioning in the biopharmaceutical landscape is attracting attention, with its commitment to innovative therapies for chronic conditions and strong revenue growth making it a noteworthy candidate for investors in healthcare innovation.
The recent pediatric sales data for Afrezza, with 428 new scripts and 487 refills, is being closely watched, and the company's ability to show strong patient demand by the time of its 3Q 2026 earnings report in November will be crucial.
Institutional ownership is currently at 70-80%, and despite some speculation about market manipulation, the stock's trading below its 50-day and 200-day moving averages and its neutral Relative Strength Index (RSI) position suggest a potential buying opportunity for investors.

Newcomers· Sep 22

Some users are speculating that MannKind Corporation may revisit the $2 price range again.
There is a theory that a wealthy individual, possibly a "rich lady boy," is buying up shares of MannKind Corporation.
Newcomers are taking note of MannKind Corporation's recent impressive recovery and are suggesting that it's a good time to follow the stock, with some users even loading up on dips.

Generated by AI

MannKind

Social

Sep 29

Bullish· Sep 25

Bearish· Sep 24

Earnings· Nov 1

Analysts· Jan 7

Announcements· Jul 24

Controversies· Jan 6

Technical Analysis· Sep 2

Regulars· Sep 29

Newcomers· Sep 22

Steven Binder sells $128,477 of MannKind (MNKD) stock

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses

MannKind at H.C. Wainwright conference: new launches lift outlook

MannKind director Steven Binder sells $127,855 in company stock

Cantor Fitzgerald reiterates Overweight on MannKind stock at $8

Also Discussed

MannKind Corporation

Company Information

Location

Steven Binder sells $128,477 of MannKind (MNKD) stock

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses

MannKind at H.C. Wainwright conference: new launches lift outlook

MannKind director Steven Binder sells $127,855 in company stock

Cantor Fitzgerald reiterates Overweight on MannKind stock at $8

Also Discussed

Social

Sep 29

Bullish· Sep 25

Bearish· Sep 24

Earnings· Nov 1

Analysts· Jan 7

Announcements· Jul 24

Controversies· Jan 6

Technical Analysis· Sep 2

Regulars· Sep 29

Newcomers· Sep 22